‘Nucleic acid-based therapeutics’ based on mRNA, are a group of technologies with potential applications in vaccination for cancer, infectious diseases and diseases requiring protein replacement therapy. Improvements in mRNA formulation and delivery using lipid nanoparticle and cationic nanoparticle encapsulation have overcome early issues with stability and complex dendritic cell (DC) loading techniques. Landmark studies have shown that
directly injected encapsulated mRNA is both safe and immunogenic triggering humoral and cellular immune responses in healthy and cancer patients.
mRNA vaccines are potentially disruptive because they provide some critical advantages over existing vaccine antigen approaches.
This MarketVIEW product consists of a detailed Executive presentation (~112 .pdf slides) and MS-Excel workbook (.xls) which gives a comprehensive overview of mRNA technologies and their potential application in the prophylatic and therapeutic setting for cancer and infectious diseases indications. An R&D pipeline analysis is provided which details all current mRNA candidates at clinical stages. Major companies and alliances are outlined with a focus on each individual program (infectious diseases). Importantly, drawing upon our VacZine Analytics research portfolio, a strategic analysis is included whereby opportunities associated with mRNA technologies are
contrasted with the competitive threat level should a new vaccine progress to licensure. This report is ideal for any client wishes to understand the potential significance of this emerging field.
THIS PRODUCT IS A SUMMARY PRESENTATION (~105 slides, .pdf) + MS Excel Worksheets